MedTrace Logo

A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

NCT07172867 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2026-02-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.

Conditions

  • Diabetes Mellitus, Type 2
  • Obesity

Interventions

DRUG

HT-6184

2mg QD

DRUG

HT-6184 Matching Placebo

2mg QD

DRUG

Semaglutide 1 mg

Semaglutide 1 mg, every week

Sponsors & Collaborators

  • Halia Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-06
Primary Completion
2026-01-23
Completion
2026-01-23

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07172867 on ClinicalTrials.gov